The stock of EyePoint Pharmaceuticals Inc (EYPT) has gone down by -11.26% for the week, with a -32.54% drop in the past month and a -58.15% drop in the past quarter. The volatility ratio for the week is 4.93%, and the volatility levels for the past 30 days are 8.03% for EYPT. The simple moving average for the past 20 days is -21.32% for EYPT’s stock, with a -32.22% simple moving average for the past 200 days.
Is It Worth Investing in EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) Right Now?
Additionally, the 36-month beta value for EYPT is 1.59. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for EYPT is 49.00M and currently, short sellers hold a 13.48% ratio of that float. The average trading volume of EYPT on May 24, 2024 was 1.17M shares.
EYPT) stock’s latest price update
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT)’s stock price has decreased by -3.14 compared to its previous closing price of 11.47. However, the company has seen a -11.26% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2024-05-16 that WATERTOWN, Mass., May 16, 2024 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Analysts’ Opinion of EYPT
Many brokerage firms have already submitted their reports for EYPT stocks, with JP Morgan repeating the rating for EYPT by listing it as a “Overweight.” The predicted price for EYPT in the upcoming period, according to JP Morgan is $35 based on the research report published on January 22, 2024 of the current year 2024.
Mizuho, on the other hand, stated in their research note that they expect to see EYPT reach a price target of $20. The rating they have provided for EYPT stocks is “Buy” according to the report published on November 02nd, 2023.
Robert W. Baird gave a rating of “Outperform” to EYPT, setting the target price at $33 in the report published on April 21st of the previous year.
EYPT Trading at -38.63% from the 50-Day Moving Average
After a stumble in the market that brought EYPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.15% of loss for the given period.
Volatility was left at 8.03%, however, over the last 30 days, the volatility rate increased by 4.93%, as shares sank -31.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -49.71% lower at present.
During the last 5 trading sessions, EYPT fell by -11.26%, which changed the moving average for the period of 200-days by -10.19% in comparison to the 20-day moving average, which settled at $13.87. In addition, EyePoint Pharmaceuticals Inc saw -51.93% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EYPT starting from GUYER DAVID R, who sale 11,625 shares at the price of $12.65 back on May 14 ’24. After this action, GUYER DAVID R now owns 5,550 shares of EyePoint Pharmaceuticals Inc, valued at $147,045 using the latest closing price.
Cormorant Asset Management, LP, the 10% Owner of EyePoint Pharmaceuticals Inc, purchase 850,000 shares at $11.86 during a trade that took place back on May 06 ’24, which means that Cormorant Asset Management, LP is holding 8,325,000 shares at $10,081,721 based on the most recent closing price.
Stock Fundamentals for EYPT
Current profitability levels for the company are sitting at:
- -1.74 for the present operating margin
- 0.91 for the gross margin
The net margin for EyePoint Pharmaceuticals Inc stands at -1.58. The total capital return value is set at -0.33. Equity return is now at value -48.07, with -32.62 for asset returns.
Based on EyePoint Pharmaceuticals Inc (EYPT), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -2.18. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -199.62.
Currently, EBITDA for the company is -73.2 million with net debt to EBITDA at 3.2. When we switch over and look at the enterprise to sales, we see a ratio of 6.26. The receivables turnover for the company is 16.59for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.08.
Conclusion
In conclusion, EyePoint Pharmaceuticals Inc (EYPT) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
